Acivir Pills: Effective Antiviral Treatment for Herpes Infections
Acivir Pills
| Product dosage: 200mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.85 | $51.00 (0%) | 🛒 Add to cart |
| 90 | $0.72 | $76.50 $65.00 (15%) | 🛒 Add to cart |
| 120 | $0.68 | $102.00 $81.00 (21%) | 🛒 Add to cart |
| 180 | $0.62 | $153.00 $111.00 (27%) | 🛒 Add to cart |
| 270 | $0.57 | $229.50 $155.00 (32%) | 🛒 Add to cart |
| 360 | $0.56
Best per pill | $306.00 $200.00 (35%) | 🛒 Add to cart |
Acivir Pills contain the active ingredient acyclovir, a nucleoside analogue DNA polymerase inhibitor specifically designed to combat herpesvirus infections. This oral antiviral medication is clinically proven to reduce the severity and duration of outbreaks while suppressing viral replication. Healthcare professionals prescribe Acivir for its targeted mechanism of action and well-established safety profile, making it a first-line treatment option for managing herpes simplex and varicella-zoster infections.
Features
- Contains 200mg, 400mg, or 800mg acyclovir as the active pharmaceutical ingredient
- Film-coated tablets for easier swallowing and improved stability
- Bioavailability of approximately 15-30% following oral administration
- Rapid conversion to active metabolite acyclovir triphosphate in infected cells
- Manufactured under GMP-certified facilities with consistent quality control
- Available in blister packs of 10, 30, or 90 tablets
Benefits
- Significantly reduces healing time for active herpes lesions
- Decreases viral shedding and transmission risk
- Suppresses recurrent outbreaks when used chronically
- Alleviates pain and discomfort associated with vesicles
- Minimizes risk of complications in immunocompromised patients
- Provides flexible dosing regimens for episodic or suppressive therapy
Common use
Acivir Pills are primarily indicated for the treatment of herpes simplex virus (HSV) infections, including genital herpes and herpes labialis (cold sores). They are also prescribed for acute management of herpes zoster (shingles) and chickenpox in immunocompetent patients. Off-label uses may include herpes prophylaxis in transplant recipients and management of herpes encephalitis maintenance therapy. The medication demonstrates particular efficacy in patients with frequent recurrences (≥6 episodes annually) where suppressive therapy is warranted.
Dosage and direction
Herpes Zoster: 800mg every 4 hours (5 times daily) for 7-10 days
Genital Herpes (Initial Episode): 200mg every 4 hours (5 times daily) for 10 days
Recurrent Genital Herpes: 200mg every 4 hours (5 times daily) for 5 days
Chronic Suppressive Therapy: 400mg twice daily for up to 12 months
Chickenpox: 20mg/kg (max 800mg) four times daily for 5 days
Administer with a full glass of water. May be taken with or without food, though consistent administration with meals may improve gastrointestinal tolerance. For patients with renal impairment (CrCl <10 mL/min), dose reduction to 200mg every 12 hours is recommended.
Precautions
Maintain adequate hydration during therapy to prevent crystalluria. Use with caution in elderly patients due to age-related renal function decline. Monitor renal function during treatment courses exceeding 10 days. Neurological symptoms require immediate evaluation as neurotoxicity may occur (especially in renal impairment). Pregnancy Category B: use only if potential benefit justifies potential risk. Breastfeeding considerations: acyclovir concentrates in breast milk (milk:plasma ratio 0.6-4.1).
Contraindications
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation. Contraindicated in patients with previous severe neurological reactions to antiviral nucleoside analogues. Not recommended for patients with CrCl <10 mL/min without adequate dose adjustment. Avoid use in patients with history of significant hepatic encephalopathy.
Possible side effect
Common (≥1%): nausea (8.2%), vomiting (2.7%), diarrhea (3.2%), headache (5.6%)
Less common (0.1-1%): dizziness, fatigue, skin rash, abdominal pain
Rare (<0.1%): leukopenia, thrombocytopenia, elevated liver enzymes
Serious: acute renal failure, neurological symptoms (agitation, confusion, coma), anaphylaxis, toxic epidermal necrolysis
Drug interaction
Probenecid: Increases acyclovir AUC by 40% and half-life by 18%
Nephrotoxic agents (aminoglycosides, cyclosporine): Enhanced renal toxicity potential
Zidovudine: May cause increased fatigue and lethargy
Mycophenolate mofetil: Potential additive effects on immunosuppression
Monitor closely when co-administering with other renally eliminated drugs
Missed dose
Take the missed dose as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed dose. Maintain regular dosing intervals to ensure consistent antiviral coverage. For patients on suppressive therapy, a single missed dose generally doesn’t significantly impact efficacy.
Overdose
Symptoms may include nausea, vomiting, lethargy, seizures, and renal impairment. Management includes gastric lavage if presented within 1 hour of ingestion. Maintain adequate hydration and urinary output. Hemodialysis significantly enhances acyclovir clearance (reducing half-life from 3 hours to 1.7 hours). Monitor renal function and neurological status for至少 48 hours post-overdose.
Storage
Store at controlled room temperature (20-25°C/68-77°F). Protect from moisture and light. Keep container tightly closed. Do not remove desiccant from packaging. Discard any tablets showing signs of deterioration or discoloration. Keep out of reach of children and pets. Do not use beyond expiration date printed on packaging.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting any new medication. Dosage and treatment duration should be determined by a qualified physician based on individual patient factors. Not all possible uses, interactions, or adverse effects are listed here.
Reviews
Clinical studies demonstrate 75-85% reduction in healing time for initial herpes episodes when treatment begins within 48 hours of symptom onset. Suppressive therapy shows 70-80% reduction in recurrence frequency among patients with frequent outbreaks. Meta-analyses confirm superior efficacy compared to placebo with favorable safety profile. Real-world evidence supports long-term use for up to 10 years with maintained efficacy and minimal resistance development.